20-May-2024
No headlines found.
Zynex to Present at the RBC Capital Markets Global Healthcare Conference
PRNewswire (Thu, 9-May 9:15 AM ET)
Zynex Executives Recognized Among Top 25 in Medical Technology
PRNewswire (Tue, 7-May 9:15 AM ET)
Zynex Reports First Quarter 2024 Financial Results
PRNewswire (Tue, 30-Apr 4:01 PM ET)
Zynex Sets First Quarter 2024 Earnings Call
PRNewswire (Thu, 18-Apr 9:15 AM ET)
Zynex Earns Prestigious 2024 Top Workplaces USA Employer Recognition Award
PRNewswire (Tue, 2-Apr 9:15 AM ET)
Zynex Reports Fourth Quarter and Full Year 2023 Financial Results
PRNewswire (Thu, 29-Feb 4:01 PM ET)
Zynex Sets Fourth Quarter and Full Year 2023 Earnings Call
PRNewswire (Thu, 22-Feb 9:15 AM ET)
Zynex Inc is engaged in the manufacturing and marketing of medical devices. It operates through one primary business segment, Electrotherapy and Pain Management Products. The business activities of the company are carried out through its subsidiaries. The company designs, manufactures, and markets medical devices that treat chronic and acute pain, as well as activate and exercise muscles for rehabilitative purposes with electrical stimulation. The company markets Zynex-manufactured products which include NexWave, NeuroMove, InWave E-Wave, and others.
Zynex trades on the NASDAQ stock market under the symbol ZYXI.
As of May 20, 2024, ZYXI stock price declined to $10.56 with 65,253 million shares trading.
ZYXI has a beta of 1.16, meaning it tends to be more sensitive to market movements. ZYXI has a correlation of 0.11 to the broad based SPY ETF.
ZYXI has a market cap of $340.03 million. This is considered a Small Cap stock.
Last quarter Zynex reported $47 million in Revenue and $.00 earnings per share. This fell short of revenue expectation by $-1 million and missed earnings estimates by -$.03.
In the last 3 years, ZYXI stock traded as high as $17.25 and as low as $4.97.
The top ETF exchange traded funds that ZYXI belongs to (by Net Assets): VTI, IWM, VXF, IWO, VTWO.
ZYXI has underperformed the market in the last year with a price return of +9.7% while the SPY ETF gained +28.2%. ZYXI has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -16.1% and -1.7%, respectively, while the SPY returned +7.0% and +2.6%, respectively.
ZYXI support price is $10.55 and resistance is $11.21 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ZYXI stock will trade within this expected range on the day.